Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Non-Current Deffered Revenue (2016 - 2022)

Fate Therapeutics' Non-Current Deffered Revenue history spans 11 years, with the latest figure at $12.4 million for Q3 2022.

  • For Q3 2022, Non-Current Deffered Revenue fell 61.9% year-over-year to $12.4 million; the TTM value through Sep 2022 reached $12.4 million, down 61.9%, while the annual FY2021 figure was $27.1 million, 41.06% down from the prior year.
  • Non-Current Deffered Revenue reached $12.4 million in Q3 2022 per FATE's latest filing, down from $17.7 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $54.7 million in Q2 2020 to a low of $1.3 million in Q1 2018.
  • Average Non-Current Deffered Revenue over 5 years is $20.3 million, with a median of $12.4 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 1277.24% in 2021, then tumbled 61.9% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $7.5 million in 2018, then tumbled by 49.67% to $3.8 million in 2019, then soared by 1119.1% to $46.0 million in 2020, then tumbled by 41.06% to $27.1 million in 2021, then plummeted by 54.26% to $12.4 million in 2022.
  • Per Business Quant, the three most recent readings for FATE's Non-Current Deffered Revenue are $12.4 million (Q3 2022), $17.7 million (Q2 2022), and $22.5 million (Q1 2022).